ALVR AlloVir

AlloVir to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

Morgan Stanley 21st Annual Global Healthcare Conference

Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET

H.C. Wainwright 25th Annual Global Investment Conference

Presentation: Tuesday, September 12, 2023 at 12:00 pm ET

A live webcast and archived replay of these presentations will be available on the Investors & Press section of the AlloVir website at .

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit or follow us on or .

EN
28/08/2023

Underlying

ALVRAlloVir

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlloVir

 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Socie...

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to...

January 28, 2026 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Pl...

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement age...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 ...

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety ...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Reports Third Quarter 2025 Financial Results and Provides Busi...

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026  Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief...

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer Highly experienced biopharma financial officer joins leadership team  CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MB...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch